HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma

Ben Davidson, Mari Bukholt Elstrand, Michael T. McMaster, Aasmund Berner, Robert J Kurman, Björn Risberg, Claes G. Trope, Ie Ming Shih

Research output: Contribution to journalArticle

Abstract

We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones. The objective of this study was to evaluate the expression and clinical role of HLA-G in effusions and corresponding solid tumors from patients diagnosed with advanced-stage ovarian carcinoma. Effusions (=148), corresponding primary tumors (=66), and metastatic lesions (=122) were analyzed using immunohistochemistry with an anti-HLA-G monoclonal antibody. HLA-G was detected in cancer cells in 49/148 (33%) effusions, 33/66 (50%) primary tumors, and 59/122 (48%) solid metastases. These differences did not reach statistical significance. Expression in effusions and solid metastases significantly correlated (P = 0.029). HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038). The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042). HLA-G expression in primary tumors and solid metastases did not correlate with any of the clinicopathologic parameters studied. HLA-G is expressed in a significant number of ovarian carcinomas at all anatomic sites. The reduced expression of HLA-G in post-chemotherapy effusions and its correlation with improved survival may be related to preferential susceptibility of HLA-G-expressing cells at this site. Our findings suggest a new role for HLA-G as a prognostic indicator in advanced-stage ovarian cancer in effusions.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalGynecologic Oncology
Volume96
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Tumor Biomarkers
HLA Antigens
Carcinoma
Drug Therapy
Neoplasms
Neoplasm Metastasis
Gastrin-Secreting Cells
Histocompatibility Antigens Class I
Survival
Ovarian Neoplasms
Immunohistochemistry
Monoclonal Antibodies

Keywords

  • Chemotherapy
  • Effusions
  • Immune response
  • Ovarian carcinoma
  • Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. / Davidson, Ben; Elstrand, Mari Bukholt; McMaster, Michael T.; Berner, Aasmund; Kurman, Robert J; Risberg, Björn; Trope, Claes G.; Shih, Ie Ming.

In: Gynecologic Oncology, Vol. 96, No. 1, 01.2005, p. 42-47.

Research output: Contribution to journalArticle

Davidson, Ben ; Elstrand, Mari Bukholt ; McMaster, Michael T. ; Berner, Aasmund ; Kurman, Robert J ; Risberg, Björn ; Trope, Claes G. ; Shih, Ie Ming. / HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. In: Gynecologic Oncology. 2005 ; Vol. 96, No. 1. pp. 42-47.
@article{ec53123cd73b43d0a58ff723ba193f69,
title = "HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma",
abstract = "We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones. The objective of this study was to evaluate the expression and clinical role of HLA-G in effusions and corresponding solid tumors from patients diagnosed with advanced-stage ovarian carcinoma. Effusions (=148), corresponding primary tumors (=66), and metastatic lesions (=122) were analyzed using immunohistochemistry with an anti-HLA-G monoclonal antibody. HLA-G was detected in cancer cells in 49/148 (33{\%}) effusions, 33/66 (50{\%}) primary tumors, and 59/122 (48{\%}) solid metastases. These differences did not reach statistical significance. Expression in effusions and solid metastases significantly correlated (P = 0.029). HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038). The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042). HLA-G expression in primary tumors and solid metastases did not correlate with any of the clinicopathologic parameters studied. HLA-G is expressed in a significant number of ovarian carcinomas at all anatomic sites. The reduced expression of HLA-G in post-chemotherapy effusions and its correlation with improved survival may be related to preferential susceptibility of HLA-G-expressing cells at this site. Our findings suggest a new role for HLA-G as a prognostic indicator in advanced-stage ovarian cancer in effusions.",
keywords = "Chemotherapy, Effusions, Immune response, Ovarian carcinoma, Survival",
author = "Ben Davidson and Elstrand, {Mari Bukholt} and McMaster, {Michael T.} and Aasmund Berner and Kurman, {Robert J} and Bj{\"o}rn Risberg and Trope, {Claes G.} and Shih, {Ie Ming}",
year = "2005",
month = "1",
doi = "10.1016/j.ygyno.2004.09.049",
language = "English (US)",
volume = "96",
pages = "42--47",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma

AU - Davidson, Ben

AU - Elstrand, Mari Bukholt

AU - McMaster, Michael T.

AU - Berner, Aasmund

AU - Kurman, Robert J

AU - Risberg, Björn

AU - Trope, Claes G.

AU - Shih, Ie Ming

PY - 2005/1

Y1 - 2005/1

N2 - We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones. The objective of this study was to evaluate the expression and clinical role of HLA-G in effusions and corresponding solid tumors from patients diagnosed with advanced-stage ovarian carcinoma. Effusions (=148), corresponding primary tumors (=66), and metastatic lesions (=122) were analyzed using immunohistochemistry with an anti-HLA-G monoclonal antibody. HLA-G was detected in cancer cells in 49/148 (33%) effusions, 33/66 (50%) primary tumors, and 59/122 (48%) solid metastases. These differences did not reach statistical significance. Expression in effusions and solid metastases significantly correlated (P = 0.029). HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038). The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042). HLA-G expression in primary tumors and solid metastases did not correlate with any of the clinicopathologic parameters studied. HLA-G is expressed in a significant number of ovarian carcinomas at all anatomic sites. The reduced expression of HLA-G in post-chemotherapy effusions and its correlation with improved survival may be related to preferential susceptibility of HLA-G-expressing cells at this site. Our findings suggest a new role for HLA-G as a prognostic indicator in advanced-stage ovarian cancer in effusions.

AB - We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones. The objective of this study was to evaluate the expression and clinical role of HLA-G in effusions and corresponding solid tumors from patients diagnosed with advanced-stage ovarian carcinoma. Effusions (=148), corresponding primary tumors (=66), and metastatic lesions (=122) were analyzed using immunohistochemistry with an anti-HLA-G monoclonal antibody. HLA-G was detected in cancer cells in 49/148 (33%) effusions, 33/66 (50%) primary tumors, and 59/122 (48%) solid metastases. These differences did not reach statistical significance. Expression in effusions and solid metastases significantly correlated (P = 0.029). HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038). The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042). HLA-G expression in primary tumors and solid metastases did not correlate with any of the clinicopathologic parameters studied. HLA-G is expressed in a significant number of ovarian carcinomas at all anatomic sites. The reduced expression of HLA-G in post-chemotherapy effusions and its correlation with improved survival may be related to preferential susceptibility of HLA-G-expressing cells at this site. Our findings suggest a new role for HLA-G as a prognostic indicator in advanced-stage ovarian cancer in effusions.

KW - Chemotherapy

KW - Effusions

KW - Immune response

KW - Ovarian carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=10044255346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044255346&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.09.049

DO - 10.1016/j.ygyno.2004.09.049

M3 - Article

VL - 96

SP - 42

EP - 47

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -